Systemic drivers behind GLP-1 obesity/diabetes treatments: shifting from weight loss to metabolic health in obesogenic environments
Original framing: “[Comment] Treatment potential of oral small-molecule GLP-1 receptor agonists” — The Lancet
The history of obesity/diabetes treatment is marked by cyclical shifts from structural interventions (e.g., public health campaigns in the early 20th century) to pharmacological solutions (e.g., insulin, metformin), often delaying systemic reforms. The current GLP-1 boom echoes past 'miracle drug' eras, such as the rise of statins for cholesterol, which masked the need for dietary and policy changes. Colonial food systems disrupted traditional diets, creating metabolic vulnerabilities that pharmaceuticals now exploit.
The GLP-1 narrative exemplifies how biomedical solutions can become complicit in systemic failures, where pharmaceutical dependency masks the obesogenic environments created by agribusiness, colonial legacies, and profit-driven healthcare.
Indigenous and cross-cultural health systems offer holistic alternatives, framing metabolic health as a communal and environmental issue rather than an individual pathology. The marginalization of these systems reflects a broader pattern of Western biomedical dominance, where 'miracle drugs' delay structural reforms. Future solutions must integrate policy reform, community-led care, and decolonized healthcare to address root causes. The trickster’s role—exposed by Hermes, Anansi, or Bakhtin—highlights the absurdity of treating a systemic crisis with individual drugs, urging us to question who benefits from the current narrative and who is left behind.